Cargando…

A Pragmatic Randomized Controlled Trial to Increase PrEP Uptake for HIV Prevention: 55-Week Results From PrEPChicago

OBJECTIVES: We tested preliminary efficacy of a peer change agent type I network intervention to increase pre-exposure prophylaxis (PrEP) linkage to care among network members connected to young Black men who have sex with men. DESIGN: Parent study is a pragmatic randomized controlled trial with 110...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, John A., Young, Lindsay, Ramachandran, Arthi, Michaels, Stuart, Cohen, Hildie, Robinson, Ishida, Alon, Leigh, Hill, Brandon, Nakasone, Sarah, Balenciaga, Mario, Motley, Darnell, Bouris, Alida, Khanna, Aditya, Ferreira, Matthew, Valente, Thomas, Schumm, Phillip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722461/
https://www.ncbi.nlm.nih.gov/pubmed/33306562
http://dx.doi.org/10.1097/QAI.0000000000002518
_version_ 1783620158879694848
author Schneider, John A.
Young, Lindsay
Ramachandran, Arthi
Michaels, Stuart
Cohen, Hildie
Robinson, Ishida
Alon, Leigh
Hill, Brandon
Nakasone, Sarah
Balenciaga, Mario
Motley, Darnell
Bouris, Alida
Khanna, Aditya
Ferreira, Matthew
Valente, Thomas
Schumm, Phillip
author_facet Schneider, John A.
Young, Lindsay
Ramachandran, Arthi
Michaels, Stuart
Cohen, Hildie
Robinson, Ishida
Alon, Leigh
Hill, Brandon
Nakasone, Sarah
Balenciaga, Mario
Motley, Darnell
Bouris, Alida
Khanna, Aditya
Ferreira, Matthew
Valente, Thomas
Schumm, Phillip
author_sort Schneider, John A.
collection PubMed
description OBJECTIVES: We tested preliminary efficacy of a peer change agent type I network intervention to increase pre-exposure prophylaxis (PrEP) linkage to care among network members connected to young Black men who have sex with men. DESIGN: Parent study is a pragmatic randomized controlled trial with 110 weeks of total follow-up. Interim midpoint analyses are performed here using participant data before crossover assignment at 55 weeks. METHODS: We randomly assigned 423 participants in Chicago to receive the network intervention, an opinion leader workshop with telephonic booster sessions, versus a time-matched control from 2016 to 2018. The consolidated surrogate outcome was PrEP referral and linkage to clinical care among network members connected to study participants and was collected from independent administrative data. RESULTS: Each study participant in the trial (n = 423) had on average 1822 network contacts who could be eligible for PrEP referral and linkage. During the 55-week observation period, PrEP referral was most likely to occur within 3 days of an intervention session compared to control [odds ratio (OR) 0.07 (0.02–0.013); P = 0.007] resulting in 1–2 referrals of network members per session. Network members with referral or linkage were more likely to be connected to study participants in the intervention arm than the control condition [aOR 1.50 (1.09–2.06); P = 0.012]. CONCLUSIONS: A peer change agent type I network intervention is preliminarily effective at diffusing PrEP through a network of individuals highly susceptible to HIV over 55 weeks. This low-intensity intervention demonstrated network-level impact among populations that have experienced limited PrEP care engagement in the United States.
format Online
Article
Text
id pubmed-7722461
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher JAIDS Journal of Acquired Immune Deficiency Syndromes
record_format MEDLINE/PubMed
spelling pubmed-77224612020-12-31 A Pragmatic Randomized Controlled Trial to Increase PrEP Uptake for HIV Prevention: 55-Week Results From PrEPChicago Schneider, John A. Young, Lindsay Ramachandran, Arthi Michaels, Stuart Cohen, Hildie Robinson, Ishida Alon, Leigh Hill, Brandon Nakasone, Sarah Balenciaga, Mario Motley, Darnell Bouris, Alida Khanna, Aditya Ferreira, Matthew Valente, Thomas Schumm, Phillip J Acquir Immune Defic Syndr Prevention Research OBJECTIVES: We tested preliminary efficacy of a peer change agent type I network intervention to increase pre-exposure prophylaxis (PrEP) linkage to care among network members connected to young Black men who have sex with men. DESIGN: Parent study is a pragmatic randomized controlled trial with 110 weeks of total follow-up. Interim midpoint analyses are performed here using participant data before crossover assignment at 55 weeks. METHODS: We randomly assigned 423 participants in Chicago to receive the network intervention, an opinion leader workshop with telephonic booster sessions, versus a time-matched control from 2016 to 2018. The consolidated surrogate outcome was PrEP referral and linkage to clinical care among network members connected to study participants and was collected from independent administrative data. RESULTS: Each study participant in the trial (n = 423) had on average 1822 network contacts who could be eligible for PrEP referral and linkage. During the 55-week observation period, PrEP referral was most likely to occur within 3 days of an intervention session compared to control [odds ratio (OR) 0.07 (0.02–0.013); P = 0.007] resulting in 1–2 referrals of network members per session. Network members with referral or linkage were more likely to be connected to study participants in the intervention arm than the control condition [aOR 1.50 (1.09–2.06); P = 0.012]. CONCLUSIONS: A peer change agent type I network intervention is preliminarily effective at diffusing PrEP through a network of individuals highly susceptible to HIV over 55 weeks. This low-intensity intervention demonstrated network-level impact among populations that have experienced limited PrEP care engagement in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 2021-01-01 2021-10-23 /pmc/articles/PMC7722461/ /pubmed/33306562 http://dx.doi.org/10.1097/QAI.0000000000002518 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Prevention Research
Schneider, John A.
Young, Lindsay
Ramachandran, Arthi
Michaels, Stuart
Cohen, Hildie
Robinson, Ishida
Alon, Leigh
Hill, Brandon
Nakasone, Sarah
Balenciaga, Mario
Motley, Darnell
Bouris, Alida
Khanna, Aditya
Ferreira, Matthew
Valente, Thomas
Schumm, Phillip
A Pragmatic Randomized Controlled Trial to Increase PrEP Uptake for HIV Prevention: 55-Week Results From PrEPChicago
title A Pragmatic Randomized Controlled Trial to Increase PrEP Uptake for HIV Prevention: 55-Week Results From PrEPChicago
title_full A Pragmatic Randomized Controlled Trial to Increase PrEP Uptake for HIV Prevention: 55-Week Results From PrEPChicago
title_fullStr A Pragmatic Randomized Controlled Trial to Increase PrEP Uptake for HIV Prevention: 55-Week Results From PrEPChicago
title_full_unstemmed A Pragmatic Randomized Controlled Trial to Increase PrEP Uptake for HIV Prevention: 55-Week Results From PrEPChicago
title_short A Pragmatic Randomized Controlled Trial to Increase PrEP Uptake for HIV Prevention: 55-Week Results From PrEPChicago
title_sort pragmatic randomized controlled trial to increase prep uptake for hiv prevention: 55-week results from prepchicago
topic Prevention Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722461/
https://www.ncbi.nlm.nih.gov/pubmed/33306562
http://dx.doi.org/10.1097/QAI.0000000000002518
work_keys_str_mv AT schneiderjohna apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT younglindsay apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT ramachandranarthi apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT michaelsstuart apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT cohenhildie apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT robinsonishida apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT alonleigh apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT hillbrandon apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT nakasonesarah apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT balenciagamario apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT motleydarnell apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT bourisalida apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT khannaaditya apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT ferreiramatthew apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT valentethomas apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT schummphillip apragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT schneiderjohna pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT younglindsay pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT ramachandranarthi pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT michaelsstuart pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT cohenhildie pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT robinsonishida pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT alonleigh pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT hillbrandon pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT nakasonesarah pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT balenciagamario pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT motleydarnell pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT bourisalida pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT khannaaditya pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT ferreiramatthew pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT valentethomas pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago
AT schummphillip pragmaticrandomizedcontrolledtrialtoincreaseprepuptakeforhivprevention55weekresultsfromprepchicago